Share This Page
Thiethylperazine malate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for thiethylperazine malate and what is the scope of freedom to operate?
Thiethylperazine malate
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for thiethylperazine malate
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 14 |
| DailyMed Link: | thiethylperazine malate at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for thiethylperazine malate
US Patents and Regulatory Information for thiethylperazine malate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TORECAN | thiethylperazine malate | INJECTABLE;INJECTION | 012754-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Thiethylperazine Malate Market Dynamics, Patent Status, and Financial Trajectory
Thiethylperazine malate is a mature phenothiazine antiemetic marketed primarily under the Torecan brand. Its composition patents expired long ago, no meaningful United States Orange Book estate is identified, and biosimilar risk is irrelevant because the product is a small-molecule drug. Commercial value is concentrated in selected national markets where legacy brand recognition, regulatory approvals, and local distribution remain more important than patent exclusivity.
The product’s financial trajectory is consistent with a late-life pharmaceutical: limited disclosed revenue, low research investment, generic or multisource competition, and gradual substitution by newer antiemetics such as ondansetron, metoclopramide, domperidone, and serotonin or neurokinin pathway agents.
What is thiethylperazine malate used for?
Thiethylperazine malate is the malate salt of thiethylperazine, a phenothiazine derivative with antiemetic and antivertigo activity. It acts primarily through dopamine receptor antagonism in the central nervous system and has additional pharmacologic effects associated with phenothiazines.
| Attribute | Detail |
|---|---|
| Active ingredient | Thiethylperazine |
| Salt form | Malate |
| Common brand | Torecan |
| Drug class | Phenothiazine antiemetic |
| Common strengths | 6.5 mg and 10 mg, depending on dosage form and country |
| Dosage forms | Tablets, suppositories, and injectable products in selected markets |
| Typical uses | Nausea, vomiting, and vertigo-related symptoms |
| ATC classification | R06AD03 in the WHO ATC system |
| Regulatory status | National-market product; no major U.S. commercial presence |
| Biosimilar classification | Not applicable |
Product information for Torecan identifies nausea, vomiting, and vertigo as principal indications. Labels also describe sedation, extrapyramidal reactions, orthostatic effects, and other phenothiazine-related risks. The safety profile limits use in some patient populations and creates a competitive disadvantage against newer agents with more targeted clinical positioning (Novartis Pharma Schweiz AG, 2023; World Health Organization, 2024).
When does thiethylperazine malate lose exclusivity?
Thiethylperazine malate lost meaningful molecule-level patent exclusivity decades ago. The active ingredient was developed during the early phenothiazine era, and any original composition or basic pharmaceutical patents would have expired under modern patent-term rules long before the current market period.
No current commercial thesis depends on an unexpired compound patent. Market access is instead controlled by:
- National marketing authorizations
- Product-specific quality requirements
- Manufacturing approvals
- Local trademarks
- Distribution arrangements
- Hospital and pharmacy procurement contracts
- Availability of alternative antiemetics
The remaining commercial protections are therefore regulatory and operational rather than patent-based.
What patents protect thiethylperazine malate?
No active, globally significant composition-of-matter patent is associated with thiethylperazine malate. Historic patents may remain relevant for documenting the origin of the molecule, but they do not create a current barrier to generic development.
A country-specific formulation or process patent could theoretically affect a particular presentation, but no widely cited active patent family has emerged as the central barrier to commercial entry. A competitor would more likely develop a conventional tablet, injectable, or suppository using established pharmaceutical technology than seek to license a proprietary delivery platform.
What is the Orange Book status of thiethylperazine malate?
Thiethylperazine malate is not a significant Orange Book product in the United States. No widely marketed U.S. reference product, active U.S. New Drug Application, or associated Orange Book patent estate is identified for Torecan or thiethylperazine malate in the current U.S. market.
The practical consequences are material:
| U.S. regulatory issue | Assessment |
|---|---|
| Commercial U.S. reference product | Not established |
| Orange Book listing | No meaningful current listing identified |
| Listed patent challenge | No meaningful target identified |
| Paragraph IV litigation | No active, commercially significant case identified |
| ANDA pathway | Dependent on an approved U.S. reference product |
| U.S. market opportunity | Limited unless a sponsor pursues a new regulatory strategy |
A company seeking U.S. entry would not appear to have a straightforward conventional ANDA opportunity without an appropriate reference product and regulatory pathway. That issue is separate from patent freedom to operate. A product can be off-patent but still commercially unattractive or procedurally difficult to register in a market where no active reference product is available.
Are there Paragraph IV challenges to thiethylperazine malate?
No material current Paragraph IV challenge is identified. The absence of litigation reflects the product’s U.S. commercial position and lack of a meaningful listed patent estate, rather than evidence of a strong patent portfolio.
A generic applicant in a country with an active national authorization would generally face ordinary registration and pharmaceutical-quality requirements. In the United States, the commercial and regulatory pathway would be more complex because thiethylperazine malate is not a mainstream currently marketed reference product.
What formulations are protected by thiethylperazine malate patents?
The established product formats are conventional dosage forms rather than high-value proprietary delivery systems.
| Formulation | Commercial assessment |
|---|---|
| Oral tablet | Most straightforward generic presentation; low technical barrier |
| Suppository | More specialized manufacturing and stability requirements |
| Injectable solution | Sterility, container closure, and supply controls increase execution risk |
| Modified-release formulation | No major commercial product or dominant patent estate identified |
| Transdermal or depot delivery | No established Torecan platform identified |
The suppository and injectable formats may provide stronger practical barriers than tablets because they require specialized manufacturing, validation, packaging, and regulatory documentation. Those barriers are not equivalent to patent exclusivity. They can reduce the number of suppliers while leaving the underlying market open.
How strong is the patent estate for thiethylperazine malate?
The patent estate is weak from a current commercial perspective.
| Patent-estate factor | Assessment |
|---|---|
| Composition patent | Expired |
| Salt patent | No current blocking estate identified |
| Formulation patents | Limited commercial relevance |
| Method-of-use patents | No dominant current estate identified |
| Manufacturing patents | Potentially process-specific, not market-wide |
| Orange Book patents | No material current U.S. estate identified |
| Freedom-to-operate risk | Low for conventional formulations, subject to country review |
| Commercial moat | Regulatory approvals, supply, and brand familiarity |
Method-of-use protection is also limited. The accepted uses, including nausea, vomiting, and vertigo, are longstanding therapeutic applications. Broad claims covering these indications would generally face validity and expiration constraints.
What is the FDA regulatory status of thiethylperazine malate?
Thiethylperazine malate is not an important current FDA-approved commercial product. Its principal presence is in national European and other international markets under local regulatory systems.
Torecan product information in Switzerland identifies national authorization and local prescribing restrictions rather than an EU-wide centralized authorization. This distinction matters because approval, reimbursement, labeling, and supply status can differ materially by country (Novartis Pharma Schweiz AG, 2023).
The product’s regulatory position is affected by several factors:
- It is an old active ingredient with limited contemporary clinical-development activity.
- Safety warnings associated with phenothiazines can restrict prescribing.
- Its indications overlap with better-known antiemetic products.
- Its market is fragmented across national authorizations.
- Regulatory maintenance costs can be disproportionate to sales in small markets.
Which companies manufacture or market thiethylperazine malate?
Torecan has historically been associated with Novartis and its predecessor companies. Current marketing rights, authorization holders, and manufacturing arrangements can vary by country. Local generic and multisource manufacturers may also supply thiethylperazine products under national brand or generic names.
A global manufacturer ranking is not available from public company disclosures. Large pharmaceutical companies generally do not report thiethylperazine revenue or production volumes separately because the product is immaterial at consolidated reporting levels.
| Commercial participant | Likely role |
|---|---|
| Novartis and related local entities | Historical and selected-market Torecan commercialization |
| National generic manufacturers | Potential supply in markets with active approvals |
| Contract manufacturers | Possible production for local authorization holders |
| Distributors | Country-specific supply and pharmacy access |
The absence of separately disclosed sales prevents a reliable ranking by manufacturer or market share.
What is the financial trajectory of thiethylperazine malate?
Thiethylperazine malate is a low-growth, late-life product. Its financial profile is driven by volume retention in niche markets rather than price expansion or new indication development.
| Financial driver | Direction |
|---|---|
| Global unit demand | Flat to declining |
| Average selling price | Low and generally pressured |
| Patent-driven pricing power | None |
| Development spending | Minimal |
| Generic competition | Persistent where approvals exist |
| Brand value | Local and declining over time |
| Revenue transparency | Very low |
| Margin profile | Dependent on manufacturing and distribution scale |
Novartis’ public financial reporting does not identify Torecan as a material standalone revenue contributor. The product is therefore unlikely to have a measurable effect on group revenue, operating profit, or valuation. Any remaining value would be contained within local product portfolios, established distribution contracts, or mature-branded portfolios rather than reported at group level (Novartis AG, 2023).
What revenue exposure does thiethylperazine malate create?
Revenue exposure is limited for diversified pharmaceutical companies. The main risks are operational:
- Loss of a national marketing authorization
- Product discontinuation caused by low volume
- Manufacturing-site changes
- Shortages of specialized injectable or suppository presentations
- Generic price erosion
- Replacement by newer antiemetic products
- Pharmacovigilance costs
For a small regional company, the product could still provide useful recurring revenue if it has a protected local registration and limited competition. That value would depend on volume, reimbursement, tender access, and manufacturing cost rather than patent life.
How does thiethylperazine malate compare with competing antiemetics?
Thiethylperazine competes in a crowded antiemetic market. Its main commercial disadvantages are age, phenothiazine-class adverse effects, and limited contemporary clinical differentiation.
| Product | Main mechanism or class | Competitive position |
|---|---|---|
| Thiethylperazine | Phenothiazine dopamine antagonist | Mature, niche, legacy product |
| Metoclopramide | Dopamine antagonist with prokinetic activity | Broad availability and lower-cost competition |
| Domperidone | Peripheral dopamine antagonist | Strong use in selected countries, with cardiac restrictions |
| Ondansetron | 5-HT3 antagonist | Established in chemotherapy, postoperative, and acute-care settings |
| Prochlorperazine | Phenothiazine dopamine antagonist | Direct class competition |
| Aprepitant and related agents | NK1 antagonists | Higher-value use in chemotherapy-related nausea |
| Dimenhydrinate and related agents | Antihistamine antiemetics | Common competition for motion-related symptoms |
Thiethylperazine retains potential utility where physicians are familiar with Torecan, where vertigo-related symptoms are treated with established local protocols, or where the product is inexpensive and readily available. It has limited ability to command premium pricing against generic alternatives.
What generic entry risks exist for thiethylperazine malate?
Generic entry risk is high in markets with an active regulatory pathway. The patent barrier is low, and conventional oral products should not require advanced formulation technology.
Generic entry may be slower for:
- Sterile injectable products
- Suppositories
- Markets with small patient populations
- Countries requiring local clinical or bioequivalence documentation
- Markets where the reference product is intermittently unavailable
- Products subject to complex national reimbursement rules
A generic launch would likely follow one of three scenarios:
Low-cost conventional tablet entry
A manufacturer launches a standard oral product after obtaining national approval. This scenario creates the greatest price and volume pressure on Torecan.
Limited multisource entry
Only one or two manufacturers remain active because the market is small. Prices may remain stable, but supply interruptions become more likely.
Market exit without replacement
The originator or local licensee withdraws because revenue cannot support regulatory maintenance and production. Physicians then move patients to other antiemetics rather than wait for a replacement thiethylperazine supplier.
What licensing deals affect thiethylperazine malate?
No recent major global licensing transaction centered on thiethylperazine malate is identified in public pharmaceutical filings. Commercial rights are more likely to move through local product transfers, distributor agreements, or portfolio transactions than through high-value global licensing.
A prospective acquirer would focus on:
- The number of active country registrations
- Remaining product authorizations
- Manufacturing-site approvals
- Historical shortage records
- Trademark ownership
- Reimbursement status
- Pharmacovigilance obligations
- Product liability exposure
- Local distributor concentration
The value of a transaction would likely be calculated from recurring local cash flow and regulatory continuity. It would not be based on future patent exclusivity.
What patent litigation affects thiethylperazine malate?
No significant current patent litigation involving thiethylperazine malate is identified. The litigation profile is materially different from that of newer branded drugs with active composition, formulation, or method-of-use patents.
The principal legal risks are more likely to involve:
- Trademark disputes involving Torecan or local brand names
- Regulatory suspension or withdrawal
- Product-liability claims
- Manufacturing and quality failures
- Supply agreements
- Distributor or licensing rights
- Advertising and labeling compliance
What is the geographic market coverage of thiethylperazine malate?
The product has a fragmented geographic footprint. It is associated primarily with national markets where Torecan or a local equivalent remains authorized and commercially supplied. There is no single integrated global market comparable to a modern specialty medicine.
Geographic performance depends on:
- National authorization status
- Local prescribing habits
- Reimbursement
- Pharmacy and hospital procurement
- Competition from metoclopramide and ondansetron
- Availability of injectable and suppository forms
- Local pharmacovigilance decisions
The product’s geographic coverage is therefore best assessed country by country. Global revenue estimates based only on the existence of a brand name would overstate its commercial scale.
Key Takeaways
- Thiethylperazine malate is a mature phenothiazine antiemetic marketed mainly under Torecan.
- Original molecule-level patent protection expired decades ago.
- No material current U.S. Orange Book estate or Paragraph IV litigation is identified.
- Biosimilar risk does not apply because thiethylperazine malate is a small molecule.
- Commercial barriers are regulatory, manufacturing, and distribution-related rather than patent-based.
- Tablets face high generic-entry risk; sterile injections and suppositories have higher practical supply barriers.
- Novartis has historically been associated with Torecan, but current rights vary by country.
- Drug-specific revenue is not separately disclosed in major public-company reporting.
- Financial value is likely concentrated in small national markets and mature-product portfolios.
- The long-term trajectory is flat to declining as newer antiemetics and generic alternatives displace the product.
FAQs
Is thiethylperazine malate still sold?
It remains authorized or marketed in selected countries, although availability varies by national product registration, manufacturer, and supply conditions.
Is Torecan the same as thiethylperazine malate?
Torecan is a principal brand associated with thiethylperazine, commonly supplied as the malate salt. Strengths and dosage forms vary by country.
Can a company launch a generic thiethylperazine tablet?
Where a national reference product and regulatory pathway exist, a conventional tablet is technically suitable for generic development. Patent protection is not the principal barrier.
Does thiethylperazine malate have biosimilar competition?
No. Biosimilars apply to biologic medicines. Thiethylperazine malate is a chemically synthesized small-molecule drug and is subject to generic-drug principles.
Is thiethylperazine malate commercially attractive for a pharmaceutical acquisition?
Only as a small mature-product asset with reliable local registrations, low manufacturing costs, and limited direct competition. Its value is unlikely to derive from patents, global growth, or U.S. market expansion.
References
-
Novartis AG. (2023). Annual report 2023. Novartis AG.
-
Novartis Pharma Schweiz AG. (2023). Torecan 6.5 mg: Fachinformation. Swissmedic.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
World Health Organization. (2024). ATC/DDD index: Thiethylperazine. WHO Collaborating Centre for Drug Statistics Methodology.
-
National Library of Medicine. (2024). Thiethylperazine: Drug information. U.S. National Library of Medicine.
More… ↓
